Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02577601 · ClinicalTrials.gov registry record · Phase 4
Impact of Combined Hormonal Contraceptives on UPA
A Phase 4 study of Contraception, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT02577601: Completed Phase 4 study of Contraception, sponsored by Oregon Health and Science University.
NCT02577601 is a Phase 4 study of Contraception that has completed, run by Oregon Health and Science University. The registered enrollment target is 36 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02577601, a Phase 4 study of Contraception, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if taking a birth control pill effects how well an emergency contraceptive pill called Ulipristal acetate (UPA) works. This type of emergency contraceptive is the most effective oral method available. However, this medication is an anti-progestin and most regular forms of birth control contain progestin (a female hormone). It is unknown if taking the two close together may make the emergency contraceptive not work well. The overall goal of this research is to improve the effectiveness of contraception for women and to better counsel women.
Primary Outcome
Following dosing with UPA, subjects underwent daily visits with ultrasound monitoring until evidence of follicle rupture (complete disappearance or \>50% reduction of the mean size of the leading follicle).
Conditions Studied
Interventions
- DRUG Ulipristal Acetate
- DRUG Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-09-08 |
| Est. Completion | 2017-06-17 |
| Phase | Phase 4 |
What the finished NCT02577601 record still lists
NCT02577601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 2 interventions - of which Ulipristal Acetate is the first listed.
NCT02577601 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02577601 about?
NCT02577601 is a clinical study titled "Impact of Combined Hormonal Contraceptives on UPA". The purpose of this research study is to determine if taking a birth control pill effects how well an emergency contraceptive pill called Ulipristal acetate (UPA) works. This type of emergency contraceptive is the most effective oral method available. However, this medication is an anti-progestin an...
What is the current status of trial NCT02577601?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2015-09-08. Estimated completion is 2017-06-17.
What conditions does trial NCT02577601 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT02577601?
The interventions under investigation include: Ulipristal Acetate (DRUG), Levonorgestrel (LNG)/Ethinyl estradiol birth control pill (DRUG).
Who is sponsoring clinical trial NCT02577601?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02577601 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02577601's enrollment target sits among peer trials
36 57th of 72 higher than 16 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
RECRUITING · Phase 4
-
Etonogestrel Implant as Emergency Contraception
RECRUITING · Phase 4
-
RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users
ACTIVE NOT RECRUITING · Phase 4
-
Study of Immediate Start of Progestin Contraceptives in Medical Abortion
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI